Within our prostate cancer portfolio, PNT2002 is our investigational PSMA targeted radiotherapeutic for the treatment of patients with metastatic castrate-resistant prostate cancer. We recently ...

预计CMS的监管更新将改善患者获得专业诊断放射性药物（包括PYLARIFY）的机会。 公司的产品管线正在推进，其中用于阿尔茨海默病的MK-6240和NAV-4694以及用于前列腺癌的PNT2002显示出前景。 Lantheus拥有8.664亿美元的现金和等价物，流动性状况良好。 公司展望 全年 ...

The Company plans to submit New Drug Applications for MK-6240 in 2025 and NAV-4694 in 2026. With respect to the SPLASH Phase 3 registrational study of PNT2002, the second interim analysis performed at ...

With respect to the SPLASH Phase 3 registrational study of PNT2002, the second interim analysis performed at 75% of protocol specified events demonstrated results for radiographic progression free ...

This structure only posts the bid and ask quotes for specific stocks dealers are willing to trade. In a purely quote-driven market structure, traders must interact directly with dealers ...

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. In a series of lawsuits filed this year, Novartis has alleged that ...

In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Lantheus (LNTH – Research Report), with a price target of $145.00. The company’s shares closed last Friday ...

for PNT2002 and PNT2003 with cash on Lantheus’ balance sheet and committed financing. The milestone-based structure under the agreements allows Lantheus to maintain its attractive financial ...